jh1

NVP-BSK805 (BSK 805) is an ATP-competitive JAK2 inhibitor.

Ropsacitinib (PF-06826647) is a selective TYK2 inhibitor, which binds to TYK2 catalytically active JH1 domain (IC50: 17 nM).

SJH1-62B is a PROTAC (proteolysis-targeting chimera) designed to target the androgen receptor (AR).

SJH1-51B is an effective PROTAC degrader of BRD4, exhibiting antitumor properties.

TyK2-IN-2 is a selective inhibitor of TYK2 (IC50s: 7 nM, 0.1 μM, and 0.05 μM for TYK2 JH2, IL-23, and IFNα).

Tyk2-IN-5 is a selective and orally active inhibitor of Tyk2 JH2 (Ki: 0.086 nM for Tyk2 JH2; IC50: 25 nM for IFNα).

Tyk2-IN-7 is an inhibitor of TYK2 JH2, binds to the TYK2 JH2 domain (IC50: 0.00053 μM; Ki.app: 0.00007 μM).

JAK1/TYK2-IN-5 (compound A1) is an inhibitor of JAK1 and TYK2, exhibiting Ki values of 0.0044 nM for TYK2JH2, 0.02 nM for JAK1 JH2, 6.9 μM for JAK1 JH1, 0.79 μM for JAK2 JH1, 0.21 μM for JAK3 JH1, and 0.55 μM for TYK2JH1. Additionally, it inhibits STAT activation mediated by TYK2/JAK1, induced by IFNα.

NVP-BSK805 trihydrochloride is a potent ATP-competitive inhibitor of JAK2, exhibiting IC50 values of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM against JAK2 JH1, JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively.

GJH-166 is an analog of dopamine that has been shown to inhibit adrenergic transmission in canines.

JH-131e-153, a diacylglycerol (DAG)-lactone, serves as a small molecule activator for the C1 domain of Munc13-1, exhibiting an activation hierarchy of WT>I590≈R592A≈W588A. This compound's C1 domain shares sequence and structure homology with protein kinase C (PKC), with an activation preference of PKCα>Munc13-1>PKCε. JH-131e-153 is implicated in the modulation of neuronal processes and holds potential for research in neurodegenerative diseases [1].